236 related articles for article (PubMed ID: 18259091)
1. Resistance to chemotherapy in cancer: a complex and integrated cellular response.
Mellor HR; Callaghan R
Pharmacology; 2008; 81(4):275-300. PubMed ID: 18259091
[TBL] [Abstract][Full Text] [Related]
2. Transcription factors and drug resistance.
Kohno K; Uchiumi T; Niina I; Wakasugi T; Igarashi T; Momii Y; Yoshida T; Matsuo K; Miyamoto N; Izumi H
Eur J Cancer; 2005 Nov; 41(16):2577-86. PubMed ID: 16209921
[TBL] [Abstract][Full Text] [Related]
3. Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Efferth T; Konkimalla VB; Wang YF; Sauerbrey A; Meinhardt S; Zintl F; Mattern J; Volm M
Clin Cancer Res; 2008 Apr; 14(8):2405-12. PubMed ID: 18413831
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of drug resistance.
Longley DB; Johnston PG
J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
[TBL] [Abstract][Full Text] [Related]
5. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy.
Damaraju VL; Damaraju S; Young JD; Baldwin SA; Mackey J; Sawyer MB; Cass CE
Oncogene; 2003 Oct; 22(47):7524-36. PubMed ID: 14576856
[TBL] [Abstract][Full Text] [Related]
6. Overview of tumor cell chemoresistance mechanisms.
Gatti L; Zunino F
Methods Mol Med; 2005; 111():127-48. PubMed ID: 15911977
[TBL] [Abstract][Full Text] [Related]
7. Establishment of in-vitro models of chemotherapy resistance.
Watson MB; Lind MJ; Cawkwell L
Anticancer Drugs; 2007 Aug; 18(7):749-54. PubMed ID: 17581296
[TBL] [Abstract][Full Text] [Related]
8. Overcoming drug resistance in patients with metastatic breast cancer.
Wong ST; Goodin S
Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
10. [Research advance on role of tumor microenvironment in mediating acquired drug resistance].
Ma XL; Xing H; Ma D
Ai Zheng; 2007 Aug; 26(8):923-6. PubMed ID: 17697561
[TBL] [Abstract][Full Text] [Related]
11. Targeting senescence pathways to reverse drug resistance in cancer.
Rebbaa A
Cancer Lett; 2005 Feb; 219(1):1-13. PubMed ID: 15694659
[TBL] [Abstract][Full Text] [Related]
12. Cancer proteomics and its application to discovery of therapy response markers in human cancer.
Smith L; Lind MJ; Welham KJ; Cawkwell L;
Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance in cancer therapy: role of the microenvironment.
Galmarini CM; Galmarini FC
Curr Opin Investig Drugs; 2003 Dec; 4(12):1416-21. PubMed ID: 14763126
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
[TBL] [Abstract][Full Text] [Related]
15. Modeling therapy resistance in genetically engineered mouse cancer models.
Rottenberg S; Jonkers J
Drug Resist Updat; 2008; 11(1-2):51-60. PubMed ID: 18165147
[TBL] [Abstract][Full Text] [Related]
16. Multifactorial nature of tumor drug resistance.
Solyanik GI
Exp Oncol; 2010 Sep; 32(3):181-5. PubMed ID: 21403614
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.
Giovannetti E; Erozenci A; Smit J; Danesi R; Peters GJ
Crit Rev Oncol Hematol; 2012 Feb; 81(2):103-22. PubMed ID: 21546262
[TBL] [Abstract][Full Text] [Related]
18. Insights into oxazaphosphorine resistance and possible approaches to its circumvention.
Zhang J; Tian Q; Chan SY; Duan W; Zhou S
Drug Resist Updat; 2005 Oct; 8(5):271-97. PubMed ID: 16154799
[TBL] [Abstract][Full Text] [Related]
19. [Cancer chemotherapy in patients older than 75 years old--from the aspect of clinical pharmacology].
Tanaka K; Okumura K
Gan To Kagaku Ryoho; 1998 Jun; 25(7):995-9. PubMed ID: 9644313
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure.
Lippert TH; Ruoff HJ; Volm M
Arzneimittelforschung; 2008; 58(6):261-4. PubMed ID: 18677966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
